Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

imary brain cancer.  It does not include any of the myriad other types of cancers.    

Linda Powers, CEO of Northwest Bio, commented that "We want to correct the misleading statements about patents that have been made by certain parties with a vested interest in slowing us down.  We have confirmed our analysis with patent experts at leading national law firms, and received supporting opinions from them.  We plan to continue correcting misleading statements by other parties, and we urge anyone who is interested in confirming the true facts to review the entire 8-year record of the Cedars Sinai/IMUC '090 patent application process, and the USPTO rejections.  The entire record is publicly available to all online from the USPTO." 

Powers concluded by stating that "We are justifiably confident that we do not infringe the '090 patent, and are prepared to assert all of our rights and remedies.  The '090 patent is neither a barrier nor even a speed bump in the way of our development and future commercialization of DCVax."

About Northwest Biotherapeutics

NW Bio is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis in both the US and Europe.  The Company has a broad platform technology for dendritic cell-based vaccines.  The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal of brain cancer.  The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in multiple other cancers.  The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.  For further information
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Ga. , Sept. 17, 2014  MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today the publication of another peer-reviewed clinical study. ... A Multi-center Randomized Controlled Clinical Trial Evaluating ... Amnion/Chorion Membrane Allografts and Multi-layer Compression Therapy vs. ...
(Date:9/17/2014)... September 17, 2014 A biodegradable ... microorganisms such as bacteria, fungi, and algae into ... methane, biomass, inorganic compounds, carbon dioxide, and humus ... customer base and improved costs, biodegradable polymers are ... viable alternative to conventional polymers. Primary factors that ...
(Date:9/17/2014)... JH Technologies announces the grand opening ... JH Technologies, a leader in sales and support of ... partnership with Leica Microsystems into the Southern California market. ... will be featured at the grand opening slated for ... is located within the JH Technologies office’s at 18025 ...
(Date:9/17/2014)... 2014 BioClinica®, Inc., a leading provider of ... three of its experts are speaking at the ... to be held September 28 to October 1 in ... also announced the innovative Compass technology, a ... trials acquired earlier this year, is up for the ...
Breaking Biology Technology:MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 2MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 3MiMedx Multi-Center Randomized, Controlled VLU Clinical Study Published In Peer-Reviewed Journal 4Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 2JH Technologies displays newest microscope imaging technology at Southern California showroom grand opening 3BioClinica to Present at 20th Annual SCDM Conference 2BioClinica to Present at 20th Annual SCDM Conference 3
... NEW YORK, July 24 American Oriental,Bioengineering, Inc. (NYSE: ... release,second quarter 2008 financial results on Monday, August 11, ... a conference call at 5:00 pm ET on August ... Listeners may,access the call by dialing 1-800-599-9816 or 1-617-847-8705 ...
... SOUTH SAN FRANCISCO, Calif., July 24 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that it will hold ... results and provide a corporate update,including an update ... lead product candidate. Jerry McMahon, Ph.D., chairman and ...
... July 24 Sagent Pharmaceuticals, Inc.,a privately-held specialty ... for injection, USP, a semisynthetic,broad-spectrum, beta-lactam antibiotic. Sagent ... vials and 6g pharmacy bulk package vials. According ... the United States were,approximately $45.7 million., "Sagent ...
Cached Biology Technology:Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
(Date:9/17/2014)... bags and their environmental impact recently scored a major ... ban on the bags, and Governor Jerry Brown is ... is not yielding without a fight, according to an ... weekly newsmagazine of the American Chemical Society. , Alexander ... anti-bag campaign logged its first small victory in 1990 ...
(Date:9/17/2014)... Copenhagen Centre for Social Evolution and Yale University offers ... weight and -length can partially predict the likelihood of ... and schizophrenia later in life. The study analyzed medical ... diagnoses for up to 30 years, and adjusted for ... published today in the Proceedings of the Royal ...
(Date:9/17/2014)... Informatics at IMIM (Hospital del Mar Medical Research Institute) ... recently published a study in eLife showing ... in the evolution of new proteins, some of which ... Ribosomes produce proteins from the instructions found in an ... is RNA containing information for the synthesis of proteins, ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Parts of genome without a known function may play a key role in the birth of new proteins 2
... treatment for stroke has taken a major step forward following ... The University of Manchester have shown in laboratory studies that ... injury and death. , The team, led by Professor Nancy ... of the first small trial of IL-1ra in patients, which ...
... of diseases , A team of international researchers ... 15 regulates inflammation, a finding with implications for ... disease, diabetes, obesity, Alzheimer's, and infections. The ... issue of Nature Genetics. , Investigators believe this ...
... Hopkins researcher, with colleagues in Sweden and at the ... view of cancer as a group of diseases with ... alterations within a cell's nuclear DNA may have to ... January issue of Nature Reviews Genetics, available online Dec. ...
Cached Biology News:Stroke treatment a step closer after trial 2Scientists pinpoint inflammation gene 2Scientists pinpoint inflammation gene 3Scientists pinpoint inflammation gene 4New view of cancer: 'Epigenetic' changes come before mutations 2
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Biology Products: